Akèy › Nefrit Lupus › New York
Etid klinik pou Nefrit Lupus nan New York
16 etid pou Nefrit Lupus ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Stony Brook Internists PC, East Setauket
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT05268289Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- Circuit Clinical, Orchard Park
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06711887A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- New York Medical College, Hawthorne
- NorthWell, New Hyde Park
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset
- Hospital for Special Surgery, New York: Division of Rheumatology, New York
- Columbia University Medical Center: Department of Medicine, Division of Rheumatology, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05201469The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- Hospital for Special Surgery, New York
- Children's Hospital at Montefiore, New York
Ap rekriteFaz 2
Laj 8 a 20 · Tout sèks · Mizajou Sep 14, 2026 · NCT05538208A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, New York
- Research Site, Syracuse
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Cohen Children's Medical Center of New York, Queens
Ap rekriteFaz 2
Laj 5 a 17 · Tout sèks · Mizajou Sep 3, 2026 · NCT05039619RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
- Icahn School of Medicine at Mount Sinai, New York
- State University of New York Upstate Medical Center (SUNY), Syracuse
Ap rekriteFaz 2
Laj 12 a 65 · Tout sèks · Mizajou Aug 24, 2026 · NCT07053800PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Buffalo Rheumatology and Medicine, PLLC, Orchard Park
Ap rekriteFaz 4
Laj 18 a 75 · Tout sèks · Mizajou Aug 3, 2026 · NCT07611214A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 4, 2026 · NCT06557265A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Montefiore Medical Center, New York
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- The Feinstein Institutes for Medical Research, Manhasset
- Columbia University Medical Center, New York
- Northwell Health, New York
- ak 1 plis
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149Safety and Efficacy of ONT01 in Lupus
- Hospital for Special Surgery, New York
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT07107659Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
- The Rogosin Institute, New York
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 4, 2025 · NCT01802034Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.